These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37600698)

  • 1. Lesion-based indicators predict long-term outcomes of pheochromocytoma and paraganglioma- SIZEPASS.
    Hanschell H; Diaz-Cano S; Blanes A; Talat N; Galatá G; Aylwin S; Schulte KM
    Front Endocrinol (Lausanne); 2023; 14():1235243. PubMed ID: 37600698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas.
    Kim KY; Kim JH; Hong AR; Seong MW; Lee KE; Kim SJ; Kim SW; Shin CS; Kim SY
    PLoS One; 2016; 11(12):e0168413. PubMed ID: 27992508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior.
    Stenman A; Svahn F; Hojjat-Farsangi M; Zedenius J; Söderkvist P; Gimm O; Larsson C; Juhlin CC
    Am J Surg Pathol; 2019 Mar; 43(3):409-421. PubMed ID: 30451732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.
    Ruff SM; Ayabe RI; Malekzadeh P; Good ML; Wach MM; Gonzales MK; Tirosh A; Nilubol N; Pacak K; Kebebew E; Patel D
    J Surg Res; 2019 Nov; 243():1-7. PubMed ID: 31146085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation and Evaluation of 5 Scoring Systems for Predicting Metastatic Risk in Pheochromocytoma and Paraganglioma.
    Li Q; Lan Z; Jiang Y; Wang R; Li Z; Jiang X
    Am J Surg Pathol; 2024 Jul; 48(7):855-865. PubMed ID: 38712603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Significance of Quantitative 123I-MIBG SPECT/CT Analysis of Pheochromocytoma and Paraganglioma.
    Nakamoto R; Nakamoto Y; Ishimori T; Togashi K
    Clin Nucl Med; 2016 Nov; 41(11):e465-e472. PubMed ID: 27607159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma: ASES score.
    Cho YY; Kwak MK; Lee SE; Ahn SH; Kim H; Suh S; Kim BJ; Song KH; Koh JM; Kim JH; Lee SH
    Surgery; 2018 Sep; 164(3):511-517. PubMed ID: 29929757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pheochromocytoma and paraganglioma with negative results for urinary metanephrines show higher risks for metastatic diseases.
    Kawashima A; Sone M; Inagaki N; Okamoto K; Tsuiki M; Izawa S; Otsuki M; Okamura S; Ichijo T; Katabami T; Takeda Y; Yoshimoto T; Naruse M; Tanabe A
    Endocrine; 2021 Oct; 74(1):155-162. PubMed ID: 34272648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
    Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological and immunohistochemical characteristics associated with metastatic and recurrent progression in pheochromocytoma/paraganglioma: A cohort study.
    Wang LL; Wei XJ; Zhang QC; Li F
    Ann Diagn Pathol; 2022 Oct; 60():151981. PubMed ID: 35660808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
    Stenman A; Zedenius J; Juhlin CC
    Surgery; 2019 Nov; 166(5):901-906. PubMed ID: 31239074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients With Malignant Pheochromocytoma and Paraganglioma.
    Zheng L; Gu Y; Silang J; Wang J; Luo F; Zhang B; Li C; Wang F
    Front Endocrinol (Lausanne); 2021; 12():684668. PubMed ID: 34234744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma.
    Li M; Prodanov T; Meuter L; Kerstens MN; Bechmann N; Prejbisz A; Remde H; Timmers HJLM; Nölting S; Talvacchio S; Berends AMA; Fliedner S; Robledo M; Lenders JWM; Pacak K; Eisenhofer G; Pamporaki C
    J Clin Endocrinol Metab; 2023 Jan; 108(2):397-404. PubMed ID: 36190922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local-Regional Recurrence of Pheochromocytoma/Paraganglioma: Characteristics, Risk Factors and Outcomes.
    Cui Y; Ma X; Gao Y; Chang X; Chen S; Lu L; Tong A
    Front Endocrinol (Lausanne); 2021; 12():762548. PubMed ID: 34899602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy.
    Parasiliti-Caprino M; Lucatello B; Lopez C; Burrello J; Maletta F; Mistrangelo M; Migliore E; Tassone F; La Grotta A; Pia A; Reimondo G; Giordano R; Giraudo G; Piovesan A; Ciccone G; Deandreis D; Limone P; Orlandi F; Borretta G; Volante M; Mulatero P; Papotti M; Aimaretti G; Terzolo M; Morino M; Pasini B; Veglio F; Ghigo E; Arvat E; Maccario M
    Hypertens Res; 2020 Jun; 43(6):500-510. PubMed ID: 31586159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Presentation and Treatment Outcomes of Children and Adolescents With Pheochromocytoma and Paraganglioma in a Single Center in Korea.
    Park H; Kim MS; Lee J; Kim JH; Jeong BC; Lee S; Lee SK; Cho SY; Jin DK
    Front Endocrinol (Lausanne); 2020; 11():610746. PubMed ID: 33584544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma.
    Eisenhofer G; Deutschbein T; Constantinescu G; Langton K; Pamporaki C; Calsina B; Monteagudo M; Peitzsch M; Fliedner S; Timmers HJLM; Bechmann N; Fankhauser M; Nölting S; Beuschlein F; Stell A; Fassnacht M; Prejbisz A; Lenders JWM; Robledo M
    Clin Chem Lab Med; 2020 Oct; 59(2):353-363. PubMed ID: 33001846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAKOTSUBO-LIKE CARDIOMYOPATHY IN A LARGE COHORT OF PATIENTS WITH PHEOCHROMOCYTOMA AND PARAGANGLIOMA.
    Gagnon N; Mansour S; Bitton Y; Bourdeau I
    Endocr Pract; 2017 Oct; 23(10):1178-1192. PubMed ID: 28704094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
    Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.